ABT vs. AMGN: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ABT and AMGN, comparing key factors like performance, valuation metrics, dividends, and financial strength.
Company Overview
ABT’s market capitalization stands at 232.41 billion USD, while AMGN’s is 156.09 billion USD, indicating their market valuations are broadly comparable.
With betas of 0.74 for ABT and 0.50 for AMGN, both stocks show similar sensitivity to overall market movements.
Symbol | ABT | AMGN |
---|---|---|
Company Name | Abbott Laboratories | Amgen Inc. |
Country | US | US |
Sector | Healthcare | Healthcare |
Industry | Medical - Devices | Drug Manufacturers - General |
CEO | Mr. Robert B. Ford | Mr. Robert A. Bradway |
Price | 133.58 USD | 290.28 USD |
Market Cap | 232.41 billion USD | 156.09 billion USD |
Beta | 0.74 | 0.50 |
Exchange | NYSE | NASDAQ |
IPO Date | March 17, 1980 | June 17, 1983 |
ADR | No | No |
Performance Comparison
This chart compares the performance of ABT and AMGN over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
This section compares the market valuation of ABT and AMGN. Key takeaways regarding their valuation, when viewed within their industry context, are presented in the commentary that follows.
- AMGN’s Forward PEG ratio of 7.43 is very high. This signifies that its current stock price is notably elevated compared to its anticipated earnings growth rate, possibly indicating that the market has already factored in, or even exceeded, realistic future performance expectations.
- AMGN’s Price-to-Book (P/B) ratio of 25.16 is very high. This suggests that investors are valuing its assets and growth potential at a considerable premium to its stated book value, often due to strong return on equity, significant intangible assets, or optimistic growth forecasts.
Symbol | ABT | AMGN |
---|---|---|
Price-to-Earnings Ratio (P/E, TTM) | 17.29 | 26.32 |
Forward PEG Ratio (TTM) | 1.73 | 7.43 |
Price-to-Sales Ratio (P/S, TTM) | 5.49 | 4.57 |
Price-to-Book Ratio (P/B, TTM) | 4.78 | 25.16 |
EV-to-EBITDA (TTM) | 21.35 | 16.53 |
EV-to-Sales (TTM) | 5.65 | 6.00 |
Dividend Comparison
AMGN provides a dividend yield of 3.19%, which is significantly higher than ABT’s 1.71%, highlighting its commitment to more generous shareholder payouts.
Symbol | ABT | AMGN |
---|---|---|
Dividend Yield (TTM) | 1.71% | 3.19% |
Financial Strength Metrics Comparison
This section evaluates the financial strength of ABT and AMGN. Noteworthy observations on their financial resilience, considered from an industry perspective, are detailed in the points that follow.
- AMGN’s Debt-to-Equity (D/E) ratio of 9.24 is very high. This signals a considerable debt load relative to equity, potentially heightening its risk during economic downturns or if interest rates rise, and may affect its financial resilience.
Symbol | ABT | AMGN |
---|---|---|
Current Ratio (TTM) | 1.78 | 1.17 |
Quick Ratio (TTM) | 1.27 | 0.88 |
Debt-to-Equity Ratio (TTM) | 0.27 | 9.24 |
Debt-to-Asset Ratio (TTM) | 0.16 | 0.64 |
Net Debt-to-EBITDA Ratio (TTM) | 0.60 | 3.92 |
Interest Coverage Ratio (TTM) | 15.39 | 3.19 |